A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS
NCT06731699
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
AML
NHL
Interventions
DRUG:
FD-001
Sponsor
Chengdu FenDi Pharmaceutical Co., Ltd.